期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

来得时联合餐时速效胰岛素治疗2型糖尿病疗效观察 被引量：1

原文传递
导出
摘要 60例应用口服降糖药血糖控制不理想的T2DM患者随机分为甘精胰岛素组(n=30)采用每晚8点注射来得时,当某餐餐后血糖控制不良时,即加用诺和锐。强化治疗组(n=30)采用三餐前30min皮下注射诺和灵R,每晚10点注射诺和灵N。目标为空腹血糖≤7.0mmol/L和餐后2h血糖≤10.0mmol/L。结果治疗后两组FBG、P2BG均较前明显下降,P2BG及血糖达标时间比较无统计学意义(P>0.05),但甘精胰岛素组FBG低于强化治疗组,低血糖事件明显少于强化治疗组,每日注射4次胰岛素患者明显少于强化组,且患者坚持用药时间明显长于强化治疗组(P<0.05)。结论甘精胰岛素联合餐时超短效胰岛素可以良好地控制高血糖,且低血糖发生率低。
作者 黄晓玲 冯佳庆 王华 吴宏 李学庆
机构地区 黑龙江省大庆龙南医院内分泌科
出处 《实用糖尿病杂志》 2010年第3期35-36,共2页 Journal of Practical Diabetology
关键词 甘精胰岛素 2型糖尿病(T2DM) 强化治疗
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献3

  • 1程伟,严钟穗.长效胰岛素类似物的临床研究进展[J].国外医学（内分泌学分册）,2003,23(4):237-239. 被引量：28
  • 2Lcporc M, PampaneUi S, FaneUi C, et al. Pharrnacokinetics and pharmacodynamics of subcutaneous injection of long - acting human insulin analog glargine, NPH insulin,and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes2004,49:2142-2148.
  • 3McKeage K,Goa KL. Insulin glargine: a review of its therapeutic use as a long - acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001 ;61 ( 11 ) : 1599 - 1624.

二级参考文献15

  • 1Ebeling P, Jansson P A, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin[J]. Diabetes Care, 1997,20 : 1287-1289.
  • 2Rosskamp R H, Park G. Long-acting insulin analogs[J].Diabetes Care,1999, 22(Suppl 2) :B109-B113.
  • 3Vajo Z, Fawcett J, Duckworth W C. Recombinant DNA technology in the treatment of diabetes [ J]. Endocr Rev, 2001,22:706-717.
  • 4McKeage K, Goa K L. Insulin Glargine [ J ]. Drugs, 2001,61 :1599-1624.
  • 5Heinemann L, Linkeschova R, Rave K. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000,23 : 644-649.
  • 6Talaulicar M, Willms B, Rosskamp R. HOE901, ein neues insulin analog zur substitution des basalen insulin-bedarfs bei type 1 diabetes[ J ]. Diabetes Stoffwechsel, 1996,5 : 3-6.
  • 7Ratner R E, Hirsch I B, Neifing J L. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes[J]. Diabetes Care ,2000,23 : 639-643.
  • 8Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes [ J ] .Diabetes Care,2000,23 : 1130-1136.
  • 9Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose(FBG) and less symptomatic hypoglycemia with QD insulin glargine(Lautus) compare to bid NPH insulin in subjects with type 1 diabetes[J]. Diabetes,2001,50( Suppl 2) :116-117.
  • 10Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine compared to bedtime NPH insulin in patients with type 2 diabetes [ J] . Diabetes, 2001,50(Suppl 2) : 112-113.

共引文献27

同被引文献31

  • 1廖勤,梁泽容,屈春梅.两种基础胰岛素类似物——地特胰岛素与甘精胰岛素治疗2型糖尿病临床效果比较[J].实用医院临床杂志,2010,7(4):42-44. 被引量：25
  • 2American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes[J]. Diabetes Care, 2005, 28: 1245-1249.
  • 3Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetologia, 2009, 52: 17-30.
  • 4Heise T, Nosek L, Ronn BB. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes[J]. Diabetes, 2004, 53: 1614-1620.
  • 5Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in thpe 2 diaketes: 28-week comparison of insulin glargine(HOE901)and NPH insulin[J]. Diabetes Care, 2001, 24(4): 631 -636.
  • 6Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime[J]. Diabetes Care, 2003, 26(5): 1490- 1496.
  • 7Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies[J]. J Diabetes Complications, 2007, 21(3): 196-204.
  • 8Plank J, Bodenlenz M, Sinner E A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long acting insulin analog detemir[J]. Diabetes Care, 2005, 28:1107-1112.
  • 9Sreenan S, Virkamaki A, Zhang K, et al. Switching from NPH insulin to once- daily insulin detemir in basal-bolus-treated patients with diabetes mellitus:data from the European cohort of the PREDICTIVE study[J]. Int J Clin Pract, 2008, 62(12): 1971- 1980.
  • 10Home E Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial[J]. Diabetes Care, 2004, 27(5): 1081-1087.

引证文献1

实用糖尿病杂志
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部